# Retatrutide Peptide

> Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist that targets appetite, glucose handling, energy expenditure, and weight loss.

Canonical: https://pepflow.app/peptides/retatrutide/

The Triple Agonist

A once-weekly triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors in obesity and metabolic-disease trials.

Weight loss

Tier A

Evidence Strong

Safety Moderate Data

FDA status Not Approved

Last reviewed August 17, 2026 52 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Retatrutide?

Retatrutide is designed to combine three metabolic signals: GIP and GLP-1 receptor agonism, plus glucagon receptor agonism. That third pathway is the defining difference from tirzepatide.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

Peer-reviewed phase 2 obesity data and sponsor-announced phase 3 obesity results report large weight reductions in studied populations. Those data make retatrutide a late-stage obesity-drug candidate, not an approved medicine.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[27\]](<https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average>)

Retatrutide now has phase 2 and peer-reviewed phase 3 type 2 diabetes data, plus liver-fat/MASLD-related evidence. Those results remain investigational until regulatory review and labeling are complete.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37385280/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>) For more context, read the [retatrutide trial-dose explainer](<https://pepflow.app/blog/retatrutide-dosage/>).

## What Retatrutide is investigated for

Retatrutide evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Body-weight reduction Injectable 86% Strong

Retatrutide has moved into late-stage investigational evidence for weight management, but it remains investigational until regulatory review and labeling are complete.[\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

#### Human evidence

Phase 2 obesity data and announced phase 3 topline results show large reductions in adults with obesity or overweight.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>)

#### Animal / mechanistic evidence

Triple agonism creates a plausible stronger metabolic effect than GLP-1-only signaling, but the human phase 2 trial is the core evidence.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

### ### Type 2 diabetes metabolic control Injectable 80% Strong

The type 2 diabetes evidence now includes phase 3 data but remains investigational; it should not be read as an approved diabetes-use pathway.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37385280/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

#### Human evidence

Phase 2 and peer-reviewed phase 3 type 2 diabetes trials support glycemic and weight effects, but the drug is not approved for diabetes.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37385280/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

#### Animal / mechanistic evidence

GIP, GLP-1, and glucagon receptor activity all affect energy and glucose metabolism.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

### ### Triple-receptor metabolic signaling Injectable 66% Moderate

Triple-receptor signaling is the defining mechanism being studied, but clinical value still has to be judged by weight, glycemic, liver, safety, and regulatory results.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/35985340/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)

#### Human evidence

Early human studies and the phase 2 program evaluate retatrutide as a triple agonist with weight, glycemic, and metabolic effects.[\[30\]](<https://pubmed.ncbi.nlm.nih.gov/36354040/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)

#### Animal / mechanistic evidence

Discovery work characterizes activity across GIP, GLP-1, and glucagon receptors, which is the mechanistic reason retatrutide is separated from single- and dual-incretin drugs.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/35985340/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

### ### Liver fat and MASH markers Injectable 65% Moderate

The liver-fat signal is promising, not a settled MASH treatment claim.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

#### Human evidence

A phase 2 substudy reported liver-fat reduction in participants with MASLD.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

#### Animal / mechanistic evidence

Weight loss and glucagon-related hepatic metabolism are plausible contributors, but clinical liver benefit needs confirmatory trials.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

## Evidence snapshot

### Overall confidence

Strong

84%

Retatrutide has strong late-stage human signals for weight management, but the evidence package remains narrower than approved incretin drugs because labeling and post-approval data are not available.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[27\]](<https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

84%

### Human evidence

Strong

Human evidence includes phase 2 obesity and type 2 diabetes trials, a peer-reviewed phase 3 type 2 diabetes trial, a liver-fat substudy, body-composition analyses, and sponsor-announced phase 3 obesity results.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37385280/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/40609566/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>)

62%

### Animal / preclinical

Moderate

Discovery and pharmacology work support triple agonism, while the page confidence is driven mainly by human trial outcomes.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/35985340/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

80%

### Mechanism support

Strong

GIP, GLP-1, and glucagon receptor activation gives a coherent rationale for appetite, body-weight, glycemic, and liver-fat effects, while also creating monitoring questions around pulse, GI tolerance, and metabolic response.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

## Forms & administration

Retatrutide administration is trial-only context. Published and registered studies use protocol-controlled once-weekly subcutaneous injection; no FDA-approved public dosing, compounding, or self-directed protocol exists.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[14\]](<https://clinicaltrials.gov/study/NCT05929066>) [\[18\]](<https://clinicaltrials.gov/study/NCT06354660>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) [\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Doses range from 1-12 mg once weekly.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[14\]](<https://clinicaltrials.gov/study/NCT05929066>) [\[15\]](<https://clinicaltrials.gov/study/NCT05929079>) [\[18\]](<https://clinicaltrials.gov/study/NCT06354660>) [\[36\]](<https://pubmed.ncbi.nlm.nih.gov/41090431/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>)

### Frequency

Taken once weekly by subcutaneous injection, with gradual dose increases.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[14\]](<https://clinicaltrials.gov/study/NCT05929066>) [\[18\]](<https://clinicaltrials.gov/study/NCT06354660>)

### Timing Considerations

Use the same injection day each week.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[14\]](<https://clinicaltrials.gov/study/NCT05929066>) [\[18\]](<https://clinicaltrials.gov/study/NCT06354660>)

### Cycle Length

Long-term treatment commonly runs 48-80 weeks.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[36\]](<https://pubmed.ncbi.nlm.nih.gov/41090431/>) [\[14\]](<https://clinicaltrials.gov/study/NCT05929066>) [\[20\]](<https://clinicaltrials.gov/study/NCT06383390>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[27\]](<https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average>)

[Full Retatrutide dosage guide](<https://pepflow.app/peptides/retatrutide/dosage/>)

## What to expect

### First weeks

Appetite and fullness may shift early as dose escalation begins, while visible weight change usually builds more gradually.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)

### 6-12 months

Weight and waist reductions can become more visible with sustained treatment, with larger changes more plausible after months of exposure than in the earliest weeks.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)

### Around 18 months

Continued supervised treatment can bring larger weight and waist changes, while the quality of weight loss depends on how much lean mass is preserved.[\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[27\]](<https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/40609566/>)

### After stopping

Appetite may rise again and weight maintenance may become harder once the active triple-receptor agonist signal is removed.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[36\]](<https://pubmed.ncbi.nlm.nih.gov/41090431/>)

## Safety profile

Retatrutide safety is still investigational. Published trials support continued study, but unapproved-product exposure has produced official toxicity concerns, and glucagon-receptor activity adds monitoring questions beyond GLP-1-only drugs.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) [\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)

### Common side effects

- Nausea [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)
- Vomiting [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)
- Diarrhea [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)

### Cautions

- Toxicity alert[\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)
- Import and supply risk[\[28\]](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>)
- Other incretin or weight-loss drugs[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

### What we don't know

Rare events, long-term safety, discontinuation effects, and special-population safety remain unsettled while phase 3 and post-approval-style evidence are still developing.[\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[16\]](<https://clinicaltrials.gov/study/NCT05882045>)

## Who Retatrutide is not for

Route-specific avoid and medical-review notes:

- **Pregnancy and special populations**

  Until labeling exists, pregnancy, breastfeeding, pediatric use, frailty, significant endocrine disease, and complex metabolic disease should be treated as trial-exclusion-level concerns.[\[12\]](<https://clinicaltrials.gov/study/NCT04881760>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Other incretin or weight-loss drugs**

  Combining retatrutide with GLP-1, GIP, amylin, or other weight-loss drugs could amplify GI, pulse, glucose, and dehydration risks; combination evidence is not established.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

## Pairing notes

### Not recommended with

**Semaglutide: overlapping GLP-1 effects** Injectable

Retatrutide and semaglutide both activate GLP-1 pathways. Overlapping them combines appetite, gastric-emptying, and glucose effects without an established combination regimen.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

**Tirzepatide: overlapping GIP and GLP-1 effects** Injectable

Retatrutide and tirzepatide both activate GIP and GLP-1 pathways. Overlapping them duplicates incretin effects and adds retatrutide's glucagon activity without an established combination regimen.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

**Cagrilintide: added amylin appetite effects** Injectable

Cagrilintide adds amylin-mediated satiety to retatrutide's GIP, GLP-1, and glucagon effects. The combination is investigational and has no established combined dosing or safety framework.[\[51\]](<https://pubmed.ncbi.nlm.nih.gov/40544433/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[28\]](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>)

## Regulatory status

### United States

United States: not FDA-approved for human use as a drug; FDA also states retatrutide cannot be used in compounding under federal law.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · Retatrutide is not FDA-approved for human use as a drug in the United States.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) | Not Listed · FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.[\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>) |

### Injectable

FDA drug approval

Not Approved

Retatrutide is not FDA-approved for human use as a drug in the United States.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

503A compounding

Not Listed

FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.[\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

### International

International status is country-specific; official Australian guidance and a Victoria Health alert highlight risks around unapproved peptide products.[\[28\]](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>) [\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)

### Sports & competition

For athletes, retatrutide may fall under WADA non-approved-substance rules because it is not approved by a governmental regulatory health authority for human therapeutic use.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

## How it works

Retatrutide is a triple agonist: it activates GLP-1, GIP, and glucagon receptors, making it different from single GLP-1 agonists and dual GIP/GLP-1 drugs.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

GLP-1 and GIP explain the satiety and glycemic side; glucagon receptor activity adds energy-expenditure and liver-metabolism biology, but also makes pulse, glucose, and tolerability interpretation more important. Receptor names alone are not enough.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

Human data make the program interesting, but retatrutide remains investigational; the mechanism does not establish approval, retail dosing rules, or safe stacking with other weight-loss drugs, especially from informal supply.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>) [\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)

## Research gaps & open questions

What the current literature has not yet settled about Retatrutide:

01

Full Phase 3 obesity results and regulatory review are still needed before retatrutide's benefits, dosing, warnings, and long-term safety can be judged. Phase 3 diabetes data do not establish approval for obesity.[\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42250575/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

02

Longer studies need to show how sustained glucagon-receptor activity affects heart rate, blood sugar, liver health, gallbladder events, muscle mass, and understudied populations.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)

03

Trials of known clinical-grade retatrutide cannot establish the safety of consumer-market products; independent testing is needed for identity, purity, and dose accuracy.[\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>) [\[28\]](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>)

## Common questions

### Is retatrutide FDA-approved?

No. Retatrutide is not FDA-approved for human use as a drug, and FDA states it cannot be used in compounding under federal law.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)

### What does triple agonist mean?

It means retatrutide activates three hormone receptors: GIP, GLP-1, and glucagon. That is the main pharmacology difference from tirzepatide.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

### Is retatrutide just stronger tirzepatide?

Not exactly. Both include GIP and GLP-1 receptor activity, but retatrutide adds glucagon receptor agonism and remains investigational.[\[11\]](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)

## Myths & misconceptions

### Myth

Large retatrutide trial weight loss means it is ready for normal use.

### Reality

Large trial results are promising but do not replace approval review, labeled manufacturing, and real-world safety monitoring.[\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

### Myth

Research-market retatrutide is the same as trial retatrutide.

### Reality

Clinical-trial material is controlled and monitored. Official health alerts about unapproved retatrutide products make that distinction important.[\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>) [\[28\]](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>)

## History & discovery

Retatrutide entered the obesity pipeline as LY3437943, a triple GIP, GLP-1, and glucagon receptor agonist. Its history is still an investigational-drug story, not an approved-product story, and that distinction should stay visible.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/35985340/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/36354040/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)

Early LY3437943 and phase 2 obesity/type 2 diabetes publications made retatrutide visible as a triple-agonist candidate with human body-weight and metabolic signals.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/35985340/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/36354040/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37366315/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37385280/>)

MASLD data and TRIUMPH materials broadened the program, while unapproved-product alerts reinforced the gap between monitored trials and informal retatrutide supply, consumer availability, and safety assumptions.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/38858523/>) [\[36\]](<https://pubmed.ncbi.nlm.nih.gov/41090431/>) [\[26\]](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>) [\[29\]](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)

## Published research 52 citations

- [\[1\] **openFDA Drugs@FDA query for retatrutide** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22retatrutide%22&limit=1>)
- [\[2\] **FDA's concerns with unapproved GLP-1 drugs used for weight loss** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>)
- [\[3\] **Triple-Hormone-Receptor Agonist Retatrutide for Obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37366315/>)
- [\[4\] **Retatrutide for type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial** The Lancet. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37385280/>)
- [\[5\] **Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial** Lancet (London, England), 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/42250575/>)
- [\[6\] **Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease** Nature Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38858523/>)
- [\[7\] **Effects of retatrutide on body composition in people with type 2 diabetes and/or obesity: a post-hoc analysis** The Lancet. Diabetes & endocrinology. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40609566/>)
- [\[8\] **Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes** The Journal of clinical endocrinology and metabolism, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/42135195/>)
- [\[9\] **The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity** Kidney international reports, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40630318/>)
- [\[10\] **Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease** Nephrology, dialysis, transplantation, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41160422/>)
- [\[11\] **Retatrutide: a triple agonist for obesity and metabolic disease** Peer-reviewed review. review.](<https://pubmed.ncbi.nlm.nih.gov/37902090/>)
- [\[12\] **Retatrutide phase 2 obesity trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT04881760>)
- [\[13\] **Retatrutide phase 2 type 2 diabetes trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT04867785>)
- [\[14\] **TRIUMPH-1 retatrutide obesity and overweight trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05929066>)
- [\[15\] **TRIUMPH-2 retatrutide obesity or overweight with type 2 diabetes trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05929079>)
- [\[16\] **TRIUMPH-3 retatrutide obesity with cardiovascular disease trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05882045>)
- [\[17\] **TRIUMPH-4 retatrutide obesity or overweight with knee osteoarthritis trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05931367>)
- [\[18\] **TRANSCEND-T2D-1 retatrutide type 2 diabetes trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT06354660>)
- [\[19\] **TRANSCEND-CKD retatrutide chronic kidney disease trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT05936151>)
- [\[20\] **TRIUMPH-Outcomes retatrutide cardiovascular and kidney outcomes trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT06383390>)
- [\[21\] **TRIUMPH-5 retatrutide versus tirzepatide obesity trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT06662383>)
- [\[22\] **TRIUMPH-6 retatrutide weight-maintenance trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT06859268>)
- [\[23\] **TRIUMPH-7 retatrutide chronic low back pain trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07035093>)
- [\[24\] **TRIUMPH-8 retatrutide obesity or overweight trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07232719>)
- [\[25\] **TRIUMPH-9 retatrutide dose-escalation trial registry record** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07357415>)
- [\[26\] **Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial** Eli Lilly and Company, 2026-05-21. human clinical.](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss>)
- [\[27\] **Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial** Eli Lilly and Company, 2025-12-11. human clinical.](<https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average>)
- [\[28\] **Understanding responsibilities for unapproved peptide products** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>)
- [\[29\] **Toxicity linked to unapproved peptide product labelled Retatrutide** Victoria Department of Health, 2026-06-19. official guidance.](<https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide>)
- [\[30\] **LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial** Lancet (London, England), 2022. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/36354040/>)
- [\[31\] **Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity** Diabetes care, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38843460/>)
- [\[32\] **Emerging pharmacotherapies for obesity: A systematic review** Pharmacological reviews, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39952695/>)
- [\[33\] **Retatrutide-A Game Changer in Obesity Pharmacotherapy** Biomolecules, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40563436/>)
- [\[34\] **LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept** Cell metabolism, 2022. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/35985340/>)
- [\[35\] **Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials** Annals of internal medicine, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39761578/>)
- [\[36\] **Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials** Diabetes, obesity & metabolism, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41090431/>)
- [\[37\] **Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?** Diabetes care, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38687506/>)
- [\[38\] **What is the pipeline for future medications for obesity?** International journal of obesity (2005), 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/38302593/>)
- [\[39\] **Gut hormones and appetite regulation** Current opinion in endocrinology, diabetes, and obesity, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38511400/>)
- [\[40\] **Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials** Metabolism: clinical and experimental, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39305981/>)
- [\[41\] **Triple Agonism Based Therapies for Obesity** Current cardiovascular risk reports, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40741227/>)
- [\[42\] **The power of three: Retatrutide's role in modern obesity and diabetes therapy** European journal of pharmacology, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39515565/>)
- [\[43\] **Weight management treatment in obesity** Medicina clinica, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40865172/>)
- [\[44\] **The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation** Metabolism: clinical and experimental, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39481534/>)
- [\[45\] **Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials** Proceedings (Baylor University. Medical Center), 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40291085/>)
- [\[46\] **Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions** Gastroenterology report, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38681750/>)
- [\[47\] **Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials** Metabolism open, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/39318607/>)
- [\[48\] **Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA** Obesity (Silver Spring, Md.), 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40685589/>)
- [\[49\] **Novel GLP-1-based Medications for Type 2 Diabetes and Obesity** Endocrine reviews, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41054801/>)
- [\[50\] **The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines** Expert opinion on investigational drugs, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40022548/>)
- [\[51\] **Coadministered cagrilintide and semaglutide in adults with overweight or obesity** New England Journal of Medicine. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40544433/>)
- [\[52\] **Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes** Eli Lilly and Company, 2026-03-19. human clinical.](<https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Incretin/amylin analog

**Tier**

A

**Evidence**

84% Strong

**Safety**

Moderate Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[52 citations](<https://pepflow.app/peptides/retatrutide/#published-research>)

**Updated**

August 17, 2026

### Potential benefits

- Body-weight reduction
- Type 2 diabetes metabolic control
- Triple-receptor metabolic signaling
- Liver fat and MASH markers

### Common side effects

- Nausea
- Vomiting
- Diarrhea

### Also known as

- Retatrutide
- LY3437943
- GIP/GLP-1/glucagon triple agonist

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Retatrutide Dosage Schedules from Clinical Trials](<https://pepflow.app/blog/retatrutide-dosage/>)
- [Retatrutide dosage guide](<https://pepflow.app/peptides/retatrutide/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
